Trial Profile
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered AL-034 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation (Part 1) and After Multiple Ascending Doses (Part 2) in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AL-034 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Alios BioPharma
- 11 Jun 2019 Status changed from recruiting to completed.
- 20 Jul 2018 Planned number of patients changed from 81 to 74.
- 25 Sep 2017 New trial record